ArticlePloS one2023
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Phase I trial combining sulfasalazine and gamma knife radiosurgery for recurrent glioblastoma.MethodsX · 2026Article
- Comparison of the predictive value of intraoperative MRI and intraoperative histopathological examination for diagnostic stereotactic biopsy yield in patients with brain gliomas.Brain & spine · 2026Article
- Independent histological validation of MR-derived radio-pathomic maps of tumor cell density using image-guided biopsies in human brain tumors.Journal of neuro-oncology · 2025Article
- Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and chemoradiation.bioRxiv : the preprint server for biology · 2025Article
- L-Sarcolysine Reduced the Mobility of Human Glioblastoma Cells, with Potential Involvement of Vimentin.OncoTargets and therapy · 2025Article
- Identification of distinct profiles of glioblastoma through the immunocapture of extracellular vesicles from patient plasma.PloS one · 2025Article
- Correlations ofMolecular and clinical oncology · 2025Article
- Significance of radiation therapy in frontal glioblastoma patients and exploration of optimal treatment modality: a real-world multiple-center study based on propensity score matching.Quantitative imaging in medicine and surgery · 2024Article
- The impact of cancer patient pathway on timing of radiotherapy and survival: a cohort study in glioblastoma patients.Journal of neuro-oncology · 2024Article
- In Vivo Evaluation ofPharmaceutics · 2024Article
- The tumour microenvironment, treatment resistance and recurrence in glioblastoma.Journal of translational medicine · 2024Review
- Speeding up Glioblastoma Cancer Research: Highlighting the Zebrafish Xenograft Model.International journal of molecular sciences · 2024Review
- Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study.Neuro-oncology practice · 2024Article
- The mutated in colorectal cancer (Frontiers in oncology · 2024Article
- High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.Frontiers in oncology · 2024Review
- The involvement of brain regions associated with lower KPS and shorter survival time predicts a poor prognosis in glioma.Frontiers in neurology · 2023Article
- Molecular landscapes of glioblastoma cell lines revealed a group of patients that do not benefit fromFrontiers in neuroscience · 2023Article
- Review
- Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapy of recurrent glioblastoma (GBM) is challenging due to lack of standard treatment. We investigated physicians' treatment choice at recurrence and prognostic and predictive factors for survival in GBM patients from Norway's two largest regional hospitals. Clinicopathological data from n = 467 patients treated at Haukeland and Oslo university hospitals from January 2015 to December 2017 was collected. Data included tumour location, promoter methylation of O6 methylguanine-DNA methyltransferase (MGMT) and mutation of isocitrate dehydrogenase (IDH), patient age, sex, extent of resection at primary diagnosis and treatment at successive tumour recurrences. Cox-proportional hazards regression adjusting for multiple risk factors was used. Median overall survival (OS) was 12.1 months and 21.4% and 6.8% of patients were alive at 2 and 5 years, respectively. Median progression-free survival was 8.1 months. Treatment at recurrence varied but was not associated with difference in overall survival (OS) (p = 0.201). Age, MGMT hypermethylation, tumour location and extent of resection were independent prognostic factors. Patients who received 60 Gray radiotherapy with concomitant and adjuvant temozolomide at primary diagnosis had 16.1 months median OS and 9.3% were alive at 5 years. Patients eligible for gamma knife/stereotactic radiosurgery alone or combined with chemotherapy at first recurrence had superior survival compared to chemotherapy alone (p<0.001). At second recurrence, combination chemotherapy with or without bevacizumab were both superior to no treatment. Treatment at recurrence differed between the institutions but there was no difference in median OS, indicating that it is the disease biology that dictates patient outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.